Literature DB >> 2979672

Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease.

J G Hardy1, J N Healey, J R Reynolds.   

Abstract

Gastrointestinal transit of an enteric coated delayed release 5-aminosalicylic acid tablet radiolabelled with 111indium has been monitored in a total of 13 patients with Crohn's disease and ulcerative colitis. More than 70% of the tablets disintegrated in the small intestine, on average 3.2 hours after emptying from the stomach. Dispersed preparation was detected in the proximal colon of all the patients, except one with an ileostomy. Mean peak plasma concentrations of 5-aminosalicylic acid and its metabolite acetyl-5-aminosalicylic acid occurred 3-4 hours after gastric emptying. The tablets provide a reliable means of drug delivery to the ileum and proximal colon.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2979672     DOI: 10.1111/j.1365-2036.1987.tb00627.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  12 in total

Review 1.  Gamma scintigraphy in the evaluation of pharmaceutical dosage forms.

Authors:  S S Davis; J G Hardy; S P Newman; I R Wilding
Journal:  Eur J Nucl Med       Date:  1992

Review 2.  Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Authors:  Yongjun Wang; Claire E Parker; Tania Bhanji; Brian G Feagan; John K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2016-04-21

Review 3.  Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

Authors:  Yongjun Wang; Claire E Parker; Brian G Feagan; John K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2016-05-09

Review 4.  [Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations].

Authors:  U Klotz
Journal:  Med Klin (Munich)       Date:  1999-02-15

5.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Authors:  D Rachmilewitz
Journal:  BMJ       Date:  1989-01-14

Review 6.  Budding Multi-matrix Technology-a Retrospective Approach, Deep Insights, and Future Perspectives.

Authors:  Anitha Sriram; Suma Tangirala; Srividya Atmakuri; Sajid Hoque; Sheela Modani; Saurabh Srivastava; Srushti Mahajan; Indrani Maji; Rahul Kumar; Dharmendra Khatri; Jitender Madan; Pankaj Kumar Singh
Journal:  AAPS PharmSciTech       Date:  2021-11-03       Impact factor: 3.246

7.  Galactomannan gum coated mucoadhesive microspheres of glipizide for treatment of type 2 diabetes mellitus: In vitro and in vivo evaluation.

Authors:  Punam Gaba; Sarbjot Singh; Monika Gaba; G D Gupta
Journal:  Saudi Pharm J       Date:  2011-03-04       Impact factor: 4.330

8.  In vivo effects of mesalazine or E. coli Nissle 1917 on microsatellite instability in ulcerative colitis.

Authors:  A Goel; A Mittal; R Evstatiev; M Nemeth; W Kruis; M Stolte; C R Boland; C Gasche
Journal:  Aliment Pharmacol Ther       Date:  2009-06-25       Impact factor: 8.171

9.  Oroileal transit of slow release 5-aminosalicylic acid.

Authors:  H Goebell; U Klotz; B Nehlsen; P Layer
Journal:  Gut       Date:  1993-05       Impact factor: 23.059

Review 10.  Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease.

Authors:  G Järnerot
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.